1. Amarin reached a settlement with the FDA over its off-label marketing lawsuit. As part of the settlement, the regulator will not appeal a previous court ruling in Amarin’s favor. (MedPage Today)
2. Mobile health apps that have privacy policies still may not keep that data private, new research found. Most apps do not have such policies and at least half say that medical information will be shared with third parties, including advertisers. (Reuters)
3. Federal officials said prescription drug spending in the U.S. rose 12.6% in 2014. Drug spending only grew 2% a year between 2008 and 2012. The government attributed the increase to increased utilization of higher-priced specialty drugs and the fact that more people have health insurance as a result of the ACA. (WSJ)
4. The Obama administration plans to test new ways to pay for prescription drugs dispensed in doctors’ offices and outpatient facilities. This includes cancer therapies and treatments for rheumatoid arthritis. One proposal would allow Medicare to pay drug companies based on how well their therapies perform in patients. (NYT)
5. Sarepta Therapeutics said it hasn’t yet received a new date from the FDA to review its drug, eteplirsen, which is being developed to treat Duchenne muscular dystrophy. The drugmaker announced it would cut about 17% of its workforce. (Reuters)
